Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Ulla Hald Buhl"'
Autor:
Ida Kappel Buhl, Troels Dreier Christensen, Anna Sofie Kappel Buhl, Ib Jarle Christensen, Eva Balslev, Ann Søegaard Knop, Bent Ejlertsen, Iben Kümler, Hella Danø, Adam Andrzej Luczak, Sven Tyge Langkjer, Søren Linnet, Erik Hugger Jakobsen, Jurij Bogovic, Vesna Glavicic, Ulla Hald Buhl, Steen Knudsen, Peter Buhl Jensen, Dorte Nielsen
Background Even with positive oestrogen receptor (ER+) status some advanced breast cancer (ABC) patients fail to benefit from endocrine therapy (ET). A method that previously predicted other drugs in various cancers was evaluated. Here multigene mark
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1f74f0164074f9f5c285dc7b7b2cb16b
https://doi.org/10.21203/rs.2.10981/v1
https://doi.org/10.21203/rs.2.10981/v1
Autor:
Hella Danoe, Thomas Jensen, Erik Jakobsen, Vesna Glavicic, Jurij Bogovic, Dorte Nielsen, Eva Balslev, Annie Rasmussen, Peter Buhl Jensen, AS Knoop, Bent Ejlertsen, Ida Kappel Buhl, Ulrik Lassen, Joergen Hansen, Ulla Hald Buhl, Sven Tyge Langkjer, Steen Knudsen, Anker Jon Hansen, Mogens Winkel Madsen, Soeren Linnet
Publikováno v:
Hugger Jakobsen, E, Nielsen, D, Danø, H, Linnet, S, Hansen, J, Lassen, U N, Balslev, E, Glavicic, V, Bogovic, J, Knudsen, S, Ejlertsen, B, Søegaard Knoop, A, Buhl, U H, Madsen, M W, Buhl, I K, Hansen, A, Jensen, T, Rasmussen, A, Jensen, P B & Langkjer, S T 2018, ' Liposomal cisplatin response prediction in heavily pretreated breast cancer patients: A multigene biomarker in a prospective phase 2 study ', Journal of Clinical Oncology, vol. 36, no. 15 Suppl., e13077 . https://doi.org/10.1200/JCO.2018.36.15_suppl.e13077
e13077Background: In an ongoing, open-label Phase 2 study liposomal cisplatin (LiPlaCis) was evaluated in metastatic breast cancer (mBC) patients selected by a cisplatin-specific mRNA-based drug re...
Autor:
Knud Mejer Nelausen, Vesna Glavicic, Anna Sofie Kappel Buhl, Steen Knudsen, Soeren Linnet, Sven Tyge Langkjer, Troels Dreier Christensen, Peter Buhl Jensen, Adam Luczak, AS Knoop, Dorte Nielsen, Eva Harder Brix, Jurij Bogovic, Eva Balslev, Ulla Hald Buhl, Iben Kümler, Bent Ejlertsen, Erik Jakobsen, Ib Jarle Christensen, Peter Michael Vestlev
Publikováno v:
Journal of Clinical Oncology. 35:e12532-e12532
e12532 Background: Exemestaneis a steroidal aromatase inhibitor used in the treatment of postmenopausal patients with estrogen receptor(ER)-positive adjuvant and advanced breast cancer. We aimed to determine the predictive value of a multigene mRNA-b
Autor:
Carsten Helleberg, P Gimsing, Annie Rasmussen, Thomas Jensen, Ulla Hald Buhl, Bruce Pratt, Annette Juul Vangsted, Niels Abildgaard, Ulf Christian Frølund, Steen Knudsen, Alastair Hansen, Mogens Winkel Madsen, Anne Lerberg Nielsen, Haatisha Jandu, Peter Buhl Jensen, Nils Brünner
Publikováno v:
Vangsted, A, Jandu, H, Jensen, P B, Madsen, M W, Gimsing, P, Jensen, T, Hansen, A, Rasmussen, A, Nielsen, A, Buhl, U, Brunner, N, Pratt, B, Frølund, U, Helleberg, C, Abildgaard, N & Knudsen, S 2016, ' APO010 sensitivity in relapsed Multiple Myeloma patients ' . < http://oncologypro.esmo.org/Meeting-Resources/ESMO-2016/APO010-sensitivity-in-relapsed-multiple-myeloma-patients >
Vangsted, A, Jandu, H, Jensen, P B, Madsen, M W, Gimsing, P, Jensen, T, Hansen, A, Rasmussen, A, Nielsen, A, Buhl, U, Brunner, N, Pratt, B, Frølund, U, Helleberg, C, Abildgaard, N & Knudsen, S 2016, ' APO010 sensitivity in relapsed Multiple Myeloma patients ' . < http://www.esmo.org/content/download/88721/1622334/file/ESMO-2016-abstracts-excl-LBA-and-press-programme.pdf >
Vangsted, A, Jandu, H, Jensen, P B, Madsen, M W, Gimsing, P, Jensen, T, Hansen, A, Rasmussen, A, Nielsen, A, Buhl, U, Brunner, N, Pratt, B, Frølund, U, Helleberg, C, Abildgaard, N & Knudsen, S 2016, ' APO010 sensitivity in relapsed Multiple Myeloma patients ' . < http://www.esmo.org/content/download/88721/1622334/file/ESMO-2016-abstracts-excl-LBA-and-press-programme.pdf >
Autor:
Peter Buhl Jensen, Dick Pluim, Steen Knudsen, Eva Balslev, Ulla Hald Buhl, Jan H.M. Schellens, Ulrik Lassen, Morten Mau-Sørensen, Mogens Winkel Madsen
Publikováno v:
Cancer Research. 76:CT154-CT154
LiPlaCis is a novel liposomal formulation of cisplatin, designed to be specifically degraded by secretory phospholipase A2 (sPLA2) which is over-expressed in tumor tissue. sPLA2 has been shown to be present in a number of different tumor tissues - e.
Fulvestrant response prediction from transcriptome data obtained from primary breast cancer biopsies
Autor:
Peter Buhl Jensen, Eva Balslev, Anker Jon Hansen, Ann Knoop, Ulla Hald Buhl, Ib Jarle Christensen, Troels Dreier Christensen, Knud Mejer Nelausen, Peter Michael Vestlev, Nils Brünner, Steen Knudsen, Annie Rasmussen, Anna Sofie Kappel Buhl, Niels Henrik Hollander, Bent Ejlertsen, Eva Harder Brix, Dorte Nielsen
Publikováno v:
Journal of Clinical Oncology. 34:e12056-e12056
e12056Background: Fulvestrant is a highly selective estrogen receptor (ER) antagonist used in the treatment of postmenopausal patients with ER-positive advanced breast cancer. To identify patients ...
Autor:
Tine Molvadgaard, Purusottam Mohapatra, Ulrik Lassen, Tommy Andersson, Chandra Prakash Prasad, Morten Mau-Soerensen, Ulla Hald Buhl, Lena Axelsson, Nils Brünner, Dorte Nielsen, Peter Grundtvig Soerensen
Publikováno v:
Molecular Cancer Therapeutics. 14:A116-A116
Most current anti-cancer therapeutic drugs are targeting the proliferation and/or survival of cancer cells while very few drugs are aimed at specifically targeting the dissemination process. Several reports have demonstrated that low-levels or lack o
Autor:
Ulla Hald Buhl, Thomas Jensen, Bruce Pratt, Annie Rasmussen, Peter Buhl Jensen, Anker Jon Hansen, Steen Knudsen, Arun Asaithambi, Nils Brünner
Publikováno v:
Molecular Cancer Therapeutics. 14:C168-C168
Irofulven, a DNA damaging semi -synthetic analog of Illudin S (phytotoxin from Omphalotus illudins, jack-o'-lantern mushroom) which in the body is activated by prostaglandin reductase, has shown promising clinical activity in a range of cancer forms
Autor:
Eric Santoni-Rugiu, Peter Buhl Jensen, Ida Kappel Buhl, Mogens Winkel Madsen, Jesper Ravn, Ib Jarle Christensen, Jens Benn Sørensen, Thomas Jensen, Nils Brünner, Jon Askaa, Anker Jon Hansen, Steen Knudsen, Ulla Hald Buhl
Publikováno v:
Publons
e18502 Background: There are no established biomarkers for prediction of clinical platinum sensitivity. A new platinum response prediction method using multigene expression is reported. Methods: We...
Autor:
Peter Buhl Jensen, Iben Kümler, Nils Brünner, Ulla Hald Buhl, Steen Knudsen, Peter Michael Vestlev, Anker Jon Hansen, Dorte Nielsen, Eva Balslev, Bent Ejlertsen, Ulrik Lassen, Anne Vibeke Lænkholm, Thomas Jensen, Ida Kappel Buhl, Morten Mau Soerensen, Pernille Braemer Hertel, Mogens Winkel Madsen, Jon Askaa
Publikováno v:
Journal of Clinical Oncology. 32:TPS1139-TPS1139
TPS1139 Background: Cisplatin has shown activity in BRCA associated breast cancer patients but generally the use of cisplatin in breast cancer has been hampered by high toxicity and low response ra...